The Changsheng Bio-Technology offices in Changchun, in northeast China. Photo: Reuters

Troubled Chinese vaccine maker Changsheng faces delisting for endangering public security under revised rules

  • Changsheng Bio-Technology, country’s second-largest vaccine producer, was fined US$1.3 billion for falsifying data and selling ineffective vaccines in July
  • According to revised rules, breaches that endanger national security, public health can lead to mandatory delisting
Topic |   Vaccine scandal in China

TOP PICKS

The Changsheng Bio-Technology offices in Changchun, in northeast China. Photo: Reuters
READ FULL ARTICLE